Aigen Investment Management’s Amicus Therapeutics FOLD Stock Holding History

Aigen Investment Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,034	Closed	-$142K	–	862
2024 Q1	$142K	Buy	+12,034	New	+$154K	0.03%	582
2023 Q4	–	Sell	-31,695	Closed	-$385K	–	888
2023 Q3	$385K	Buy	+31,695	New	+$409K	0.07%	447
2023 Q2	–	Sell	-21,401	Closed	-$237K	–	825
2023 Q1	$237K	Buy	+21,401	New	+$264K	0.03%	487
2022 Q2	–	Sell	-12,095	Closed	-$115K	–	596
2022 Q1	$115K	Buy	+12,095	New	+$113K	0.02%	491
2021 Q2	–	Sell	-22,827	Closed	-$226K	–	566
2021 Q1	$226K	Buy	+22,827	New	+$353K	0.03%	504
2020 Q1	–	Sell	-2	Closed	–	–	1363
2019 Q4	$0	Buy	+2	New	+$18	﹤0.01%	1124

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Aigen Investment Management's FOLD Position: Q2 2024 in Review

Aigen Investment Management sold out of Amicus Therapeutics (FOLD) in Q2 2024, closing a stake of 12,034 shares — an estimated $142K sold.

Aigen Investment Management first reported a position in FOLD in Q4 2019 and held it in 6 quarters. The position peaked at $385K in Q3 2023. 258 funds tracked by Wall St. Rank hold FOLD as of Q2 2024.

Aigen Investment Management reported no remaining Amicus Therapeutics position as of Q2 2024 after selling out during the quarter.
Aigen Investment Management sold 12,034 Amicus Therapeutics shares in Q2 2024, an estimated $142K.
Aigen Investment Management first reported a position in Amicus Therapeutics in Q4 2019 and held it in 6 quarters.
Aigen Investment Management's Amicus Therapeutics position peaked at $385K in Q3 2023.
258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2024.

Based on Aigen Investment Management's 13F filing for Q2 2024, filed 9 Aug 2024.